Mitotane (Lysodren)

Mitotane, commonly known by the brand name Lysodren, is an adrenocorticolytic medication used to treat hyperadrenocorticism (Cushing's disease) in dogs. This powerful medication works by selectively destroying portions of the adrenal cortex, the part of the adrenal gland responsible for producing cortisol and other steroid hormones. By reducing the functional capacity of the adrenal glands, mitotane effectively lowers the excessive cortisol production that characterizes Cushing's disease, providing relief from this serious endocrine disorder that significantly impacts quality of life in affected dogs.

The mechanism of action of mitotane involves cytotoxic effects specifically targeting the cells of the adrenal cortex, particularly the zona fasciculata and zona reticularis, which are responsible for glucocorticoid and androgen production. The medication causes progressive destruction of these adrenal cortical layers, effectively reducing the gland's ability to produce cortisol. This action is irreversible at the cellular level, meaning that destroyed adrenal tissue does not regenerate. The goal of therapy is to destroy enough of the adrenal cortex to normalize cortisol production without causing complete adrenal insufficiency, which requires careful monitoring and dose adjustment throughout treatment.

Mitotane is available in tablet and capsule form for oral administration in dogs. The medication is lipophilic (fat-soluble), which has important implications for absorption and administration. Giving mitotane with food, particularly fatty food, significantly enhances absorption and is recommended for optimal therapeutic effect. Treatment with mitotane occurs in two distinct phases: an initial loading phase designed to achieve rapid control of cortisol excess, followed by a maintenance phase that sustains the therapeutic effect long-term. Each phase has different dosing strategies and monitoring requirements.

The safety profile of mitotane requires extremely careful attention due to the medication's potent and irreversible effects on the adrenal glands. While effective for controlling Cushing's disease, mitotane can cause serious complications if not properly managed, including potentially life-threatening adrenal insufficiency. Close veterinary supervision with regular monitoring tests is absolutely essential throughout treatment. Owners must be educated about signs of both inadequate treatment and excessive adrenal suppression, as prompt response to changes in the dog's condition can prevent serious complications. Despite these challenges, mitotane remains an important treatment option for canine Cushing's disease when properly supervised.

The primary indication for mitotane in dogs is the treatment of hyperadrenocorticism, commonly known as Cushing's disease or Cushing's syndrome. This endocrine disorder is characterized by chronic overproduction of cortisol by the adrenal glands, leading to a constellation of clinical signs that significantly impair quality of life. Cushing's disease is one of the most common endocrine disorders affecting middle-aged and older dogs, making effective treatment options critically important in veterinary medicine. Mitotane has been used for decades as a primary treatment for this condition.

Pituitary-dependent hyperadrenocorticism (PDH) represents the most common form of Cushing's disease in dogs, accounting for approximately 80 to 85 percent of cases. In PDH, a tumor in the pituitary gland produces excessive amounts of adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to overproduce cortisol. Mitotane is effective for PDH because it reduces the adrenal glands' capacity to respond to the excessive ACTH stimulation, thereby lowering cortisol production regardless of how much ACTH is being released by the pituitary tumor.

Adrenal-dependent hyperadrenocorticism (ADH), caused by tumors within the adrenal gland itself, accounts for the remaining 15 to 20 percent of Cushing's cases. These adrenal tumors autonomously produce cortisol without requiring ACTH stimulation. Mitotane can be used to treat ADH, though surgical removal of the affected adrenal gland is often the preferred treatment when the tumor is amenable to surgery. For dogs with inoperable adrenal tumors or when surgery is not feasible, mitotane provides a medical management option.

The clinical signs of Cushing's disease that mitotane therapy aims to resolve include increased thirst and urination (polyuria and polydipsia), increased appetite, abdominal enlargement (pot-bellied appearance), hair loss and skin changes, muscle weakness, lethargy, and panting. These signs develop gradually and can significantly reduce quality of life for affected dogs. Without treatment, Cushing's disease also increases risk of secondary complications including diabetes mellitus, urinary tract infections, hypertension, and blood clots. Effective treatment with mitotane can improve or resolve many of these clinical signs.

The selection of mitotane versus alternative treatments for Cushing's disease involves weighing several factors. Trilostane has become the most commonly used medical treatment due to its different mechanism and safety profile, but mitotane remains an important option, particularly for dogs that do not respond adequately to trilostane or cannot tolerate it. Mitotane may also be preferred in certain clinical scenarios based on the veterinarian's experience and the individual patient's needs. Cost considerations, monitoring requirements, and owner preferences also influence treatment selection.

Dosing of mitotane in dogs requires careful individualization and close veterinary supervision due to the medication's potent effects and narrow therapeutic margin. Treatment occurs in two distinct phases with different dosing strategies. The initial loading or induction phase uses higher doses to achieve rapid reduction in cortisol production, followed by a maintenance phase with lower, less frequent doses to sustain the therapeutic effect. The veterinarian determines all doses based on the individual patient's weight, condition, and response to treatment. Owners should never adjust doses independently.

The loading phase of mitotane therapy typically involves daily dosing at approximately 25 to 50 milligrams per kilogram of body weight per day, often divided into two doses. During this phase, the dog is monitored closely for signs of adequate cortisol suppression, which typically occurs within 5 to 14 days in most patients. Some veterinarians modify this traditional approach, using lower doses over longer periods to reduce the risk of complications. The loading phase continues until specific endpoints are reached, as determined by ACTH stimulation testing and clinical assessment, or until signs of cortisol deficiency develop.

Treatment duration with mitotane extends throughout the dog's life once initiated for Cushing's disease. After the loading phase achieves adequate cortisol suppression, maintenance therapy is required to sustain the effect. Maintenance dosing is typically much lower than loading doses, often given once or twice weekly rather than daily. The maintenance dose and frequency are determined by monitoring tests and clinical response, with adjustments made as needed to maintain optimal cortisol control without causing adrenal insufficiency.

Administration of mitotane should always occur with food to enhance absorption. Because mitotane is lipophilic, fatty foods significantly improve its uptake from the gastrointestinal tract. Giving the medication with a meal or fatty treat is essential for consistent therapeutic effect. Without food, absorption is erratic and less complete, potentially resulting in inadequate cortisol suppression despite appropriate dosing. Owners should establish a consistent routine for administration with regular meals.

Monitoring requirements during mitotane therapy are extensive, particularly during the loading phase. ACTH stimulation tests are performed to assess adrenal function and guide dosing decisions. During the loading phase, owners must observe their dog closely for signs of decreased appetite or interest in food, vomiting, diarrhea, lethargy, or weakness, which could indicate the therapeutic endpoint or developing cortisol deficiency. Any of these signs should prompt immediate veterinary contact, withholding of further doses until evaluation, and potential administration of glucocorticoids if prescribed by the veterinarian.

Missed doses should be handled according to veterinary guidance specific to the treatment phase. During loading, if signs of cortisol deficiency are present, doses should not be given and the veterinarian should be contacted. During maintenance, a missed dose should be given as soon as remembered unless it is close to the next scheduled dose. The veterinary team should be informed of missed doses so monitoring can be adjusted if needed. Maintaining consistent dosing is important for stable disease control during maintenance therapy.

Mitotane's potent mechanism of destroying adrenal tissue creates significant potential for adverse effects, making careful monitoring essential throughout treatment. Understanding these potential effects helps owners recognize problems early and respond appropriately. The goal of therapy is to balance effective cortisol reduction against the risk of excessive adrenal destruction, which requires close collaboration between the owner and veterinary team.

The most common and expected effects of mitotane relate to successful reduction in cortisol production. As cortisol levels decrease, dogs typically show decreased appetite, decreased thirst and urination, and changes in activity level. During the loading phase, these changes indicate the medication is working and help determine when to transition to maintenance dosing. However, these same signs can also indicate excessive cortisol suppression, making differentiation between therapeutic effect and over-treatment challenging without monitoring tests.

Gastrointestinal side effects are frequently observed in dogs receiving mitotane, including vomiting, diarrhea, and loss of appetite. These effects can occur independently of adrenal suppression, as mitotane can directly irritate the gastrointestinal tract. Giving the medication with food helps reduce gastric irritation. Persistent or severe gastrointestinal signs warrant veterinary evaluation to distinguish between direct drug effects and signs of cortisol deficiency. Some dogs may require supportive care including antiemetics or gastroprotectants during treatment.

Neurological effects can occur in some dogs treated with mitotane, including lethargy, weakness, incoordination, and in rare cases, more severe neurological signs. These effects may relate to direct drug toxicity, cortisol deficiency, or in dogs with pituitary tumors, growth of the tumor during treatment. Severe neurological signs require immediate veterinary evaluation. Dogs with large pituitary tumors may be at increased risk for neurological complications and may require additional monitoring or alternative treatment approaches.

The most serious adverse effect of mitotane is iatrogenic hypoadrenocorticism, essentially drug-induced Addison's disease. This occurs when the medication destroys too much of the adrenal cortex, resulting in inability to produce adequate cortisol. Signs include severe lethargy, weakness, vomiting, diarrhea, collapse, and potentially life-threatening Addisonian crisis. This complication can be fatal without prompt recognition and treatment. Dogs developing signs of hypoadrenocorticism require immediate veterinary care and emergency glucocorticoid administration. Owners are often provided with prednisone to give at home if concerning signs develop, pending veterinary evaluation.

Mitotane is contraindicated in dogs with known hypersensitivity to the medication. Any dog that has experienced severe adverse reactions to previous mitotane treatment should not receive the medication again without careful veterinary consideration of the risks and benefits. Alternative treatments for Cushing's disease should be explored for dogs that cannot tolerate mitotane.

Dogs with concurrent serious illnesses may not be appropriate candidates for mitotane therapy. The stress of significant illness combined with the potent effects of adrenal suppression can create dangerous situations. Dogs with uncontrolled diabetes mellitus should have their diabetes stabilized before initiating mitotane, as the rapid changes in cortisol levels during treatment can dramatically affect blood glucose control. Dogs with severe hepatic disease may have altered drug metabolism affecting both efficacy and toxicity. Significant renal disease also warrants careful consideration before starting mitotane.

Pregnancy represents an absolute contraindication for mitotane use. The medication has significant teratogenic potential and can cause fetal harm. Female dogs receiving mitotane should not be bred, and the medication should be discontinued well in advance of any planned breeding. If pregnancy is discovered in a dog on mitotane, immediate veterinary consultation is necessary to discuss the risks and options. The medication should also be used with extreme caution in lactating dogs due to potential excretion in milk.

Dogs with pre-existing hypoadrenocorticism (Addison's disease) or marginal adrenal function should not receive mitotane, as further reduction in adrenal capacity could cause life-threatening adrenal insufficiency. Similarly, dogs receiving glucocorticoid therapy for other conditions may not be appropriate mitotane candidates, as the interaction between exogenous steroids and mitotane effects complicates management. Dogs that have previously developed iatrogenic Addison's disease from mitotane are generally not retreated with this medication. Additionally, very young dogs or very debilitated patients may not tolerate the rigors of mitotane therapy and its required monitoring.

Comprehensive disclosure of all medications and supplements to the veterinarian is essential before initiating mitotane therapy. Drug interactions can significantly affect mitotane's efficacy and safety, and the complexity of managing Cushing's disease requires full understanding of all factors affecting the patient. This includes prescription medications, over-the-counter products, supplements, and any previous or concurrent treatments.

Interactions with other medications affecting the central nervous system or adrenal function are particularly important. Spironolactone, an aldosterone antagonist sometimes used for concurrent conditions, can interact with mitotane's effects on adrenal function. Ketoconazole, which has its own cortisol-lowering properties, may have additive effects with mitotane, requiring careful dose adjustment if used concurrently. Phenobarbital and other drugs that induce liver enzymes can increase mitotane metabolism, potentially requiring higher doses for therapeutic effect but also increasing the risk of toxicity.

The interaction between mitotane and exogenous glucocorticoids requires careful management. Dogs on mitotane often need prednisone supplementation, either routinely during treatment or on an emergency basis if signs of cortisol deficiency develop. The veterinarian must balance the disease-suppressing effects of mitotane against the supplemental glucocorticoid needs of the patient. Insulin requirements in diabetic dogs can change dramatically during mitotane therapy as cortisol levels fluctuate, requiring close monitoring and frequent insulin dose adjustments.

Monitoring for drug interactions involves regular assessment of the dog's clinical status and laboratory parameters throughout mitotane treatment. Changes in other medications should prompt evaluation of whether mitotane dosing needs adjustment. The veterinary team should be informed of any new medications, supplements, or treatments being considered so potential interactions can be assessed before adding them to the regimen. The complexity of mitotane therapy means that all aspects of the dog's medical care should be coordinated through the primary veterinarian managing the Cushing's disease.

General precautions for mitotane therapy begin with the critical importance of accurate diagnosis before initiating treatment. Cushing's disease should be definitively diagnosed through appropriate testing before starting mitotane, as the medication's effects are potent and largely irreversible. Testing typically includes ACTH stimulation testing, low-dose dexamethasone suppression testing, and potentially additional tests to differentiate between pituitary and adrenal causes. Treating a misdiagnosed condition with mitotane could cause serious harm.

Handler safety precautions are essential when working with mitotane. The medication is a potential human carcinogen, and handlers should minimize exposure. Pregnant women, women who may become pregnant, and nursing mothers should not handle mitotane tablets or capsules. All handlers should wear disposable gloves when administering the medication and should wash hands thoroughly afterward. Tablets should not be crushed or broken, as this creates dust that could be inhaled. If accidental exposure occurs, the affected area should be washed immediately and medical advice sought if significant exposure has occurred.

Monitoring during mitotane therapy is not optional but rather an essential component of safe treatment. ACTH stimulation tests are performed multiple times during the loading phase and periodically during maintenance to assess adrenal function. Clinical monitoring by the owner is equally important, with daily observation for signs of cortisol deficiency during loading and ongoing awareness during maintenance. Owners must understand the signs requiring immediate veterinary contact and have emergency prednisone available as prescribed by the veterinarian. Without proper monitoring, the risks of mitotane therapy increase substantially.

Special populations requiring additional caution include dogs with large pituitary tumors, who may experience tumor growth or neurological complications during treatment. Senior dogs may have reduced tolerance for the metabolic demands of treatment. Dogs with concurrent diabetes require intensive management during the cortisol fluctuations of mitotane loading. Working or performance dogs may experience prolonged recovery of stamina after treatment initiation.

Owner commitment and understanding are prerequisites for successful mitotane therapy. The medication requires consistent administration with food, careful daily monitoring during loading, recognition of signs requiring intervention, and compliance with regular veterinary monitoring appointments. Owners must be willing and able to administer emergency prednisone if prescribed and understand when to withhold mitotane doses. The veterinary team should thoroughly educate owners before initiating therapy and provide written instructions for reference.

Proper storage of mitotane protects both the medication's stability and household members from unnecessary exposure. Tablets should be stored at controlled room temperature, typically between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius), protected from light and moisture. The medication should be kept in its original container with the cap tightly secured. Storage locations should be away from areas where the container might be accidentally opened or where tablets could be dropped and lost.

Specific handling requirements for mitotane reflect its classification as a hazardous drug. Disposable gloves should be worn when handling tablets, and hands should be washed thoroughly after handling even when gloves are used. Tablets should not be crushed, broken, or chewed, as this creates hazardous dust. If a tablet needs to be split for dosing, this should be done carefully with appropriate precautions to minimize dust and contamination. Handling should occur in a well-ventilated area, and surfaces that contact the medication should be cleaned afterward.

Safety and disposal considerations for mitotane extend beyond typical medication precautions due to its hazardous nature. The medication should be stored in a secure location inaccessible to children, pets, and anyone who should not be exposed to it. Special attention is needed in multi-pet households to prevent accidental ingestion by other animals. Pregnant women, women who may become pregnant, and nursing mothers should not handle the medication at all, and alternative arrangements for administration should be made if the primary caregiver falls into these categories. Disposal of unused or expired mitotane should follow local regulations for hazardous pharmaceutical waste, which may require specific disposal procedures through veterinary offices, pharmacies, or designated waste facilities rather than standard household disposal methods.

Most dogs respond similarly to mitotane therapy regardless of breed, though certain breeds have higher prevalence of Cushing's disease and thus represent a larger proportion of treated patients. Dosing is determined by body weight and individual response rather than breed-specific factors. The fundamental principles of treatment apply across all breeds, with individualization based on each patient's response to therapy.

Breeds with documented higher prevalence of hyperadrenocorticism include Poodles (particularly Miniature and Toy varieties), Dachshunds, Beagles, Boston Terriers, Boxers, Yorkshire Terriers, and German Shepherds, among others. While these breed predispositions affect the likelihood of diagnosis, they do not typically alter how dogs respond to mitotane once therapy is initiated. Veterinarians may have heightened awareness for Cushing's disease signs in predisposed breeds, potentially leading to earlier diagnosis and treatment.

Size considerations are particularly important for mitotane dosing given the medication's narrow therapeutic margin. Giant breed dogs require careful dose calculation to ensure adequate effect without excessive toxicity. Small and toy breed dogs need precise dosing, as small variations in dose represent larger percentage differences in these patients. The wide range of dog sizes means that some patients require very small doses, potentially necessitating careful tablet splitting or use of compounded formulations for accurate dosing. Weight should be measured accurately before initiating treatment and rechecked if significant body condition changes occur during therapy.

Age-related considerations affect mitotane therapy primarily because Cushing's disease itself is predominantly a condition of middle-aged and older dogs. Most affected dogs are over 6 years of age at diagnosis. Senior dogs may have concurrent age-related conditions affecting their tolerance of treatment and overall prognosis. Hepatic and renal function tend to decline with age, potentially affecting drug metabolism and elimination. Older dogs may also be more susceptible to the adverse effects of cortisol fluctuations during treatment. The veterinarian will consider the patient's overall health status and life expectancy when recommending treatment approaches for geriatric patients with Cushing's disease.

Trilostane, sold under the brand name Vetoryl, has become the most commonly used medical treatment for canine Cushing's disease and represents the primary alternative to mitotane. Unlike mitotane's cytotoxic mechanism that destroys adrenal tissue, trilostane works by inhibiting enzymes necessary for cortisol synthesis, producing a reversible rather than permanent effect on adrenal function. This reversibility is considered a safety advantage, as discontinuation of trilostane allows cortisol production to resume. Trilostane requires once or twice daily dosing compared to mitotane's maintenance schedule of once or twice weekly, but many veterinarians and owners prefer its safety profile.

Surgical treatment options exist for some dogs with Cushing's disease, particularly those with adrenal tumors amenable to removal. Adrenalectomy, surgical removal of the affected adrenal gland, can provide definitive cure for adrenal-dependent Cushing's disease if the tumor is successfully removed. However, surgery carries significant risks and requires specialized surgical expertise. For pituitary-dependent Cushing's, hypophysectomy (removal of the pituitary tumor) is performed at specialized centers but is not widely available. Medical management with mitotane or trilostane remains the most common approach for most dogs with Cushing's disease.

Complementary approaches to managing dogs with Cushing's disease include supportive care for the various complications of the condition. Dietary management may help control weight and metabolic parameters. Treatment of concurrent conditions such as diabetes mellitus, hypertension, or urinary tract infections is essential. Some dogs benefit from medications to address specific symptoms while primary treatment takes effect. Regular monitoring and follow-up care are critical components of successful Cushing's disease management regardless of which primary treatment is used. Owners should work closely with their veterinary team to optimize all aspects of their dog's care and never make changes to Cushing's disease treatment without professional guidance.